GlassScriptPhysician profile
Crystal Jean Connors
NPI 1629357272
$5,387.93
in general payments reported to CMS, 2019-2025
47 companies · $804 in 2025
The $804 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,436 · 2022: $2,098 · 2023: $588 · 2024: $461 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,853.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $748.69 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $488.88 | 2021-2025 | |
| Pfizer INC. | $477.07 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $438.48 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $365.52 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $364.67 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $239.35 | 2022-2025 | Otezla, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $208.66 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $207.84 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $191.98 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.10 | 2021-2022 | |
| Dexcom, INC. | $147.78 | 2021-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $139.65 | 2022 | |
| Antares Pharma, INC. | $139.13 | 2022 | |
| Intuitive Surgical, INC. | $96.98 | 2024 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Connors listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.